摘要
背景：心血管疾病(CVD)是人类健康的头号杀手。全球人口老龄化,CVD造成老年人过早死亡和残疾,导致严重的社会经济负担。因此,迫切需要采取措施预防老年人CVD。目前,国际上关于高危人群心血管风险的评估及管理是CVD预防研究的热点。在我国,老年人高血压、糖尿病、高血脂等CVD危险因素未得到有效控制；对老年人心血管风险的评估与管理尚待大力开展。CVD一级预防的干预模式尚不成熟,有待深入研究。本项目拟通过调查老年人心管风险及CVD相关知识知晓现况,探讨CVD相关知识知晓水平与心血管风险的相关性；进一步开展老年人心血管风险评估与综合干预,探索有效的CVD一级预防的干预模式；同时,检测炎症相关因子在评估与监测心血管风险中的作用。
目的：1.了解老年人心血管风险及CVD相关知识知晓现况,探讨CVD相关知识知晓水平与心血管风险的相关性；2.通过对老年人的心血管风险的评估与个体化综合干预,探讨综合干预对老年人CVD认知、健康行为依从性、CVD自我管理水平及生活质量、CVD危险因素、心血管风险、血清中炎症相关因子hsCRP、visfatin、IL-6TNF-α水平的影响,并分析炎症相关因子与心血管风险的相关性；3.观察巨噬细胞脂质蓄积及泡沫化与炎症相关因子表达的影响,初步探讨血清中炎症相关因子变化的原因。
方法：1.现况研究：采取整群随机抽样方法,抽取衡阳市南华大学附一医院、南华大学附二医院进行健康体检的1200名老年人。利用自制老年人社会人口学及体检一般项目调查表、自制CVD预警症状及危险因素知识问卷,采用面对面访谈、健康指标测量、实验室生化指标检测等方式收集资料；使用2008年WHO/ISH《心血管风险评估与管理袖珍指南》对老年人进行心血管事件10年风险评估。2.随机临床实验研究：从本研究第一部分研究对象中招募200名心血管风险大于10%的老年人作为研究对象,检测血压、血糖、血脂、体重指数(BMI)及炎症相关因子(hsCRP、visfatin、IL-6、TNF-α)等,分析其与心血管风险的相关性；严格遵循匹配原则,采用分层随机法将200名老年人分为对照组与干预组,每组各100人,开展老年人心血管风险评估与综合干预实验研究。对照组根据统一要求开展常规管理,干预组在常规管理的基础上,根据目前衡阳市老年人CVD防治的薄弱环节开展个体化综合干预。利用自制老年人社会人口学及体检一般项目调查表、自制CVD预警症状及危险因素知识问卷、简明生活质量问卷、CVD自我管理问卷,采用面对面访谈、健康指标测量、实验室生化指标检测等方式收集干预前后资料,综合分析干预组与对照组的干预效果。3.实验研究：使用不同剂量oxLDL结合阿托伐他汀处理THP-1巨噬细胞,采用油红O染色观察THP-1巨噬细胞脂质蓄积及泡沫化情况,采用酶联免疫吸附试验检测培养上清中visfatin、 IL-6、TNF-α的表达情况,采用免疫细胞化学法和western blot检测细胞visfatin表达情况。
结果：1.本研究的受访对象共计1200名老年人,实际获得1120份有效问卷,对问卷进行综合分析,结果显示：①衡阳市老年人CVD危险因素的控制不理想：高血压、高血脂、高血糖患病率分别为37.5%、36.2%、18.9%,服药率分别为：43.6%、7.6%、16.4%。②衡阳市老年人心血管事件10年风险较高：心血管风险<10%的有222人(19.8%),心血管风险10%-<40%的有510人(45.5%),心血管风险≥40%的有388人(34.6%)。③衡阳市老年人的CVD知识认知水平较低：脑卒中及心脏病发作的预警症状的认知水平很低(平均得分为3.10,总分10分);CVD危险因素的认知水平较低(平均得分为4.98,总分15分)；有心血管病老年人对CVD知识认知水平高于无心血管病老年人(P<0.05)；无心血管病老年人中,CVD知识认知水平越低,心血管风险越高。④CVD知识认知水平与年龄、受教育水平、是否有心血管病史、心血管风险水平等存在不同程度相关性。2.①检测干预前不同心血管事件10年风险老年人的相关指标,结果显示,除甘油三酯外,不同级别心血管风险老年人的收缩压、空腹血糖、总胆固醇、HDL-C、LDL-C、BMI、hsCRP、visfatin、IL-6、 TNF-α的差异均有统计学意义(P<0.05)；随着心血管风险升高,收缩压、空腹血糖、总胆固醇、LDL-C、BMI、血清hsCRP、wisfatin、 IL-6、TNF-α亦升高。②本研究对象200名老年人中,178人(对照组86人,干预组92人)完成了干预六个月后的各项指标的测量,随访率为89%。干预后,两组CVD相关知识平均得分都有显著升高(P<0.05),对照组得分低水平人数明显减少而中水平人数明显增多,干预组得分低水平人数明显减少而得分高水平人数明显增多(P<0.05)；与对照组相比,干预组效果更佳,干预后的CVD知识得分高水平人数明显多于对照组(P<0.05)。③干预后,对照组与干预组健康相关行为、CVD自我管理水平及生活质量均有所提高,且与对照组相比,干预组效果更佳(P<0.05),但在对提高戒烟率及高血压服药率方面,两组效果无显著性差异(P>0.05)。④干预后,干预组收缩压、空腹血糖、TG、TC、LDL-C、BMI均降低,HDL-C升高(P<0.05),而对照组变化不明显(TG除外)(P>0.05)。⑤干预后,干预组有15人心血管风险累计降低了16级,4人累计升高4级,净降低12级,心血管风险≥40%的人数减少5人；干预后,对照组有6人心血管风险累计降低了6级,5人累计升高5级,净降低1级,心血管风险≥40%的人数减少1人。⑥干预后,干预组血清visfatin、IL-6、 TNF-α水平较干预前明显下降(P<0.05)；对照组各项血清炎症因子水平虽有下降,但差异无统计学意义(P>0.05)；干预前后,随着心血管风险的变化血清hsCRP、visfatin、IL-6、TNF-α水平相应变化(P<0.05)。3.①oxLDL能促进THP-1巨噬细胞脂质蓄积及泡沫化,且呈剂量依赖性；阿托伐他汀能减少THP-1巨噬细胞脂质蓄积；②THP-1巨噬细胞脂质蓄积越多,培养上清中visfatin、IL-6、TNF-α表达越高,细胞中visfatin的表达亦越高。
结论：1.衡阳市老年人CVD危险因素的控制不理想,CVD知识知晓水平较低,心血管风险水平较高；CVD知识知晓水平与年龄、受教育水平、是否有心血管病史、心血管风险水平存在不同程度相关性。2.综合干预可有效提高老年人CVD知识知晓水平、健康行为依从性、CVD自我管理水平及生活质量,可有效降低老年人血压、血糖、血脂、BMI等CVD危险因素及血管事件10年风险；综合干预对降低心血管风险的效果明显优于常规管理。3.血清炎症因子hsCRP、visfatin、IL-6、TNF-α与心血管风险及泡沫细胞形成存在相关性,可能用于心血管风险评估与监测。
Background:Cardiovascular disease (CVD) is the most leading cause of human death worldwide. As the global population aging, CVD causes premature death and disability in the older adults, leading to serious social and economic burden. Therefore, there is an urgent need to take measures to prevent the epidemic of cardiovascular disease in the older adults. Cardiovascular risk assessment and management in high-risk groups is a research hotspot on CVD prevention. In China, hypertension, diabetes, high cholesterol and other CVD risk factors have not been effectively controlled in the older adults. Therefore, it is essential to carry out the assessment and management of cardiovascular risk, in the older adults. And the intervention mode for the primary prevention of cardiovascular disease is not yet mature, needing in-depth study. This project is to to investigate the relationship between cardiovascular risk and awareness of CVD knowledge by investigating the current situation of cardiovascular risk and awareness of CVD knowledge in older adults; and to carry out cardiovascular risk assessment and comprehensive intervention in the older adults to explore effective intervention model for primary prevention of cardiovascular disease; further to detect the role of inflammatory cytokines in the assessing and monitoring of cardiovascular risk.
Objectives:The purposes of this study were to:1. describe the current situation of cardiovascular risk and awareness of CVD knowledge in older adults, and to investigate the relationship between cardiovascular risk and awareness of CVD knowledge.2. explore the effect of cardiovascular risk assessment and individualized comprehensive intervention on awareness of CVD knowledge, health behavior adherence, CVD self-management, quality of life, CVD risk factors, cardiovascular risk, and serum inflammatory cytokines hsCRP, visfatin, IL-6, TNF-a levels, and to understand the correlation of inflammatory cytokines with cardiovascular risk.3. observe the effect of lipid accumulation on the expression of inflammatory factors in THP-1macrophage to explore the mechanism on the changes of serum related inflammatory cytokines.
Methods:1. A cross-sectional descriptive study.1200older adults were included by a cluster random sampling method, consecutively admitted to the health examination centers of the first and the second affiliated hospitals of University of South China. Socio-demographic data and knowledge of early warning symptoms and risk factors of cardiovascular disease were collected by face-to-face interviews using two self-designed questionnaires. Other data was collected by health measurement and laboratory biochemical detection. The cardiovascular risk of the older adults was assessed using the2008WHO/ISH Pocket Guide for cardiovascular risk assessment and management.2. A randomized clinical experimental study.200older adults with cardiovascular risk greater than10%were recruited from the research subjects in the first part of the study. Blood pressure, blood sugar, blood lipids, body mass index (BMI) and inflammatory factors (hsCRP Visfatin, IL-6, TNF-α) were tested to analyze their correlation with cardiovascular risk.200older adults were divided into control group(n=100) and intervention group(n=100) following the principle of matching and stratified random strictly. An experimental study on cardiovascular risk assessment and comprehensive intervention for the older adults was carried out. The control group was given the routine management, and the intervention group was given the individualized comprehensive intervention on the basis of routine management. Socio-demographic data and knowledge of early warning symptoms and risk factors of cardiovascular disease were collected by face-to-face interviews using two self-designed questionnaires. Status of Quality of Life and CVD self-management were assessed using Quality of Life Questionnaire and CVD self-management questionnaire. Other data was collected by health measurement and laboratory biochemical detection. The cardiovascular risk of the elderly was assessed using the2008WHO/ISH Pocket Guide for cardiovascular risk assessment and management. All data were collected before and after intervention. Comprehensive analysis of the intervention effects of the intervention and the control group was carried out.3. Experimental study. THP-1macrophages were treated using different doses of oxLDL combined with atorvastatin. Lipid accumulation in THP-1macrophages was detected by oil red O staining. Expression of visfatin, IL-6and TNF-a in the culture supernatants were detected by enzyme-linked immunosorbent assay. Expression of visfatin, IL-6and TNF-a in THP-1macrophages were detected using immunocytochemical method and western blot.
Results:1. A total of1200older adults people participated in the study, and1120valid questionnaires were obtained.①The control of CVD risk factors of the older adults was not ideal in Hengyang City. The prevalence of hypertension, dyslipidemia, hyperglycemia were37.5%,36.2%,18.9%and rates of medication treatment were:43.6%,7.6%,16.4%respectively. The10-year risk of cardiovascular events was higher in the older adults.②There were222(19.8%) older adults whose cardiovascular risk were<10%,510(45.5%) older adults whose cardiovascular risk were10%～-<40%of, cardiovascular risk≥40%of388(34.6%).③There was a lower level of CVD knowledge awareness in the older adults in Hengyang City. The awareness of stroke and heart attack warning symptoms was low (average score was3.10out of10points), and the awareness of cardiovascular disease risk was low (average score was4.98out of15points). The knowledge level of the older adults with cardiovascular disease was higher than the older adults without cardiovascular disease (P<0.05). The lower the CVD knowledge level, the higher the cardiovascular risk in the older adults.④The education level, history of cardiovascular disease, cardiovascular risk level were significantly associated with the level of CVD knowledge awareness in different degrees (P<0.05).2.①In addition to triglycerides, systolic blood pressure, fasting glucose, total cholesterol, HDL-C, LDL-C; BMI The hsCRP, visfatin, IL-6, TNF-a, the differences were statistically significant associated with the different levels of cardiovascular risk in the older adults (P<0.05). With the increasing of cardiovascular risk, the systolic blood pressure, fasting glucose, total cholesterol, LDL-C, BMI, serum hsCRP, visfatin, IL-6and TNF-a also increased.②A total of200older people participated in this study, and178people (86in control group,92in intervention group) completed all the measurement after the six month intervention. The follow-up rate was89%. After the intervention, the average score of CVD knowledge in the two groups have increased (P<0.05).In the control group, the number of older people with low score decreased and those with intermediate score increased significantly; in the intervention group, the number of older people with low score decreased and those with high score increased significantly (P<0.05). Compared with the control group, the effect of the intervention group was better, the number of older people with high score was significantly more than the control group after the intervention (P<0.05).③After the intervention, the health-related behavior of the control and intervention group, the level of CVD self-management and quality of life have improved. Compared with the control group, the effect of the intervention group was better (P<0.05). But there was no significant difference in the increase of smoking quit rates and the rate of high blood pressure medication taking between the two groups (P>0.05).④After the intervention, except (TG), the systolic blood pressure, fasting glucose, TG, TC, LDL-C, BMI decreased and HDL-C increased in the intervention group (P<0.05), while the control group did not change significantly,(P>0.05).⑤After the intervention, in the intervention group, there were15older adults whose cardiovascular risk reduced16degree cumulatively,4older adults elevated4degree cumulatively, a net reduction of12degree, and a decrease of5older adults with cardiovascular risk≥40%. In the control group, there were6older adults whose cardiovascular risk reduced6degree cumulatively,5older adults elevated5degree cumulatively, a net reduction of5degree, and a decrease of1older adult with cardiovascular risk≥40%.⑥After the intervention, serum visfatin, IL-6, TNF-a levels in the intervention group decreased significantly (P<0.05), but the hsCRP difference was not statistically significant (P>0.05). The level of serum inflammatory factors in the control group decreased after the intervention, but the difference was not significant (P>0.05).3.①oxLDL could promote lipid accumulation in THP-1macrophage in a dose-dependent manner. Atorvastatin can reduce lipid accumulation in THP-1macrophage;②The more lipid accumulation in THP-1macrophage, the higher expression of visfatin, IL-6, TNF-a in culture supernatant, and the higher expression of visfatin THP-1macrophage.
Conclusion:1. The control of CVD risk factors of the older adults was not ideal in Hengyang City. The lower awareness of CVD knowledge, the higher cardiovascular risk in the older adults. The education level, history of cardiovascular disease, cardiovascular risk level were significantly associated with the level of CVD knowledge awareness.2. The comprehensive intervention could effectively improve the awareness of CVD knowledge, health behavior adherence, CVD self-management and quality of life; and reduce CVD risk factors, cardiovascular risk, serum inflammatory cytokines. The effect of comprehensive intervention on cardiovascular risk reduction was significantly superior to the routine management.3. There was correlation between serum inflammatory cytokines hsCRP, visfatin, IL-6, TNF-a and cardiovascular risk. These inflammatory cytokines might be used for assessing and monitoring of cardiovascular risk.
引文
[1]World Health Organization. Cardiovascular disease:Global atlas on cardiovascular disease prevention and control [M]. WHO,2011.
[2]卫生部心血管病防治研究中心编著.中国心血管病报告[M].北京：中国大百科全书出版社,2011.
[3]Laura L. Hayman, Liz Helden, et al. Braun, A life course approach to cardiovascular disease prevention[J]. Journal of Cardiovascular Nursing,2011, 26(4 Suppl):822-834.
[4]Klieman L, Hyde S, Berra K. Cardiovascular disease risk reduction in older adults[J]. Journal of Cardiovascular Nursing,2006,21(45):827-839.
[5]Resolution WHA61.14. WHO 2008-2013 Action plan for the global strategy for prevention and control of noncommunicable diseases. Geneva[M], World Health Organization,2008.
[6]United Nations. World Population Prospects:The 2004 Revision[M]. United Nations Publication,2005.
[7]胡大一.心血管病预防的新目标、新思路和新策略.上海医学,2010,33(5)：395-396.
[8]潘淑芝.浅谈心血管病危险因素及预防.中外医疗,2009,13：170.
[9]世界卫生组织.心血管疾病预防(心血管风险评估和管理袖珍指南)[M].日内瓦：世界卫生组织出版处,2008：1-23.
[10]Alwan H, William J, Viswanathan B, et al. Perception of cardiovascular risk and comparison with actual cardiovascular risk[J]. Eur J Cardiovasc Prev Rehabil,2009,16(5):556-561.
[11]Nguyen TT, Liao Y, Gildengorin G, et al. Cardiovascular risk factors and knowledge of symptoms among Vietnamese Americans[J]. J Gen Intern Med. 2009,24(2):238-43.
[12]Brega AQ Noe T, Loudhawk-Hedgepeth C, et al. Cardiovascular knowledge among urban American Indians and Alaska Natives:first steps in addressing cardiovascular health[J]. Prog Community Health Partnersh,2011, 5(3):273-279.
[13]Medrela-Kuder E. Junior secondary and secondary school students'knowledge level about atherosclerosis risk factors and prevention[J]. Rocz Panstw Zakl Hig,2012,63(2):219-223.
[14]Lutfiyya MN, Lipsky MS, Bales RW, et al. Disparities in knowledge of heart attack and stroke symptoms among adult men:an analysis of behavioral risk factor surveillance survey data[J]. J Natl Med Assoc,2008,100(10):1116-1124.
[15]Lutfiyya MN, Bardales R, Bales R, et al. Awareness of heart attack and stroke symptoms among Hispanic male adults living in the United States[J]. J Immigr Minor Health,2010,12(5):761-768.
[16]Poomsrikaew O, Ryan CJ, Zerwic JJ. Knowledge of heart attack symptoms and risk factors among native Thais:a street-intercept survey method[J]. Int J Nurs Pract,2010,16(5):492-498.
[17]Gill R, Chow CM. Knowledge of heart disease and stroke among cardiology inpatients and outpatients in a Canadian inner-city urban hospital[J]. Can J Cardiol,2010,26(10):537-540.
[18]Fang J, Gillespie C, Keenan NL, et al. Awareness of heart attack symptoms among US adults in 2007, and changes in awareness from 2001 to 2007[J]. Future Cardiol,2011,7(3):311-320.
[19]Lutfiyya MN, Swanoski M, Akers M, et al. PS2-04:Knowledge of Heart Attack and Stroke Symptomology:A Cross-sectional Comparison of Rural and Non-rural US Adults[J]. Clin Med Res,2012,10(3):172.
[20]Lundelin K, Graciani A, Garcia-Puig J, et al. Knowledge of stroke warning symptoms and intended action in response to stroke in Spain:a nationwide population-based study[J]. Cerebrovasc Dis,2012,34(2):161-168.
[21]Mata J, Frank R, Gigerenzer G Symptom recognition of heart attack and stroke in nine European countries:a representative survey[J]. Health Expect.2012 Mar 6.
[22]Kim EM, Hwang S Y, Kim AL. Knowledge of stroke and heart attack symptoms and risk factors among rural elderly people:a questionnaire survey[J]. Korean Circ J,2011,41(5):259-264.
[23]Lambert C, Vinson S, Shofer F, et al. The Relationship between Knowledge and Risk for Heart Attack and Stroke. J Stroke Cerebrovasc Dis.2012 Mar 10.
[24]卢永吉,李娟生,申希平,等.兰州市社区居民心血管疾病认知及危险因素和就医意向分析[J].中国慢性病预防与控制,2010,8(5)：457-459.
[25]甲丽蓉.心血管事件可逆性危险因素的分布与认知调查[J].中国医药指南,2011,9(6)：33-35.
[26]胡钦.住院冠心病患者心血管危险因素管理调查[D].硕士论文.内科学,2010.
[27]舒占坤,蔡乐,董峻,等.昆明市石林县农村中老年居民心血管疾病危险因素及其聚集性研究[J].中国慢性病预防与控制,2009,17(5)：517-518.
[28]王克伟.云南省罗平县农村居民心血管疾病危险因素的人群聚集现状及影响因素研究[D].硕士论文,流行病学与卫生统计学.昆明医学院公共卫生学院,2011.
[29]饶穗丽,徐贝尔.心血管疾病危险因素和相关行为模式的社区医疗调查及干预的探讨[J].职业与健康,2010,26(13)：1530-1531.
[30]邢丽丽,常春,王威,等.北京市东城区35-59岁社区居民心血管疾病风险评估[J].中国健康教育,2011,27(4)：254-260.
[31]Gill R, Chow CM. Knowledge of heart disease and stroke among cardiology inpatients and outpatients in a Canadian inner-city urban hospital [J]. Can J Cardiol,2010,26,537-540.
[32]Hickey A, O'Hanlon A, McGee H, et al. Stroke awareness in the general population:knowledge of stroke risk factors and warning signs in older adults [J]. BMC Geriatr,2009,9:35.
[33]Sloma A, Backlund LG, Strender LE et al. Knowledge of stroke risk factors among primary care patients with previous stroke or TIA:a questionnaire study [J]. BMC Fam Pract,2010,11:47.
[34]陈东周,张鹏,何义林,等.泰州市大学生心血管疾病危险因素认知调查[J].中国学校卫生,2011,31(11)：1317-1318.
[35]张淑枝.冠心病患者出院时心血管危险因素认知情况调查[D].硕士论文,内科学,河北医科大学,2011.
[36]甘俊玲,金建强,郑艳玲,等.武汉市心血管病危险因素相关知识知晓状况调查[J].中国社会医学杂志,2010,27(3)：155-156.
[37]周毅,刘燕,张中喜,等.脑卒中预防知识知晓情况调查[J].实用预防医学,2010,17(5)：859-860.
[38]吴泽秀,佘秋群,陈秀,等.神经内科患者家属脑卒中预防知识知晓状况分析[J].泸州医学院学报,2011,34(5)：633-636.
[39]ZHANG Qing-tan, HU Da-yi, YANG Jin-gang, et al. Public knowledge of heart attack symptoms in Beijing residents [J]. Chinese Medical Journal,2007, 120(18):1587-1591.
[40]Zeng Y, He GP, Yi GH, et al. Knowledge of stroke warning signs and risk factors among patients with previous stroke or TIA in China [J]. J Clin Nurs, 2012,21(19pt20):2886-2895.
[41]World Health Organization. Cardiovascular disease:Global atlas on cardiovascular disease prevention and control [M]. WHO,2011.
[42]卫生部心血管病防治研究中心.中国心血管病报告(2011)[J].北京：卫生部,2011.
[43]胡钦.住院冠心病患者心血管危险因素管理调查[D].硕士论文.内科学,2010.
[44]Mazon-Ramos P. Cardiovascular risk in the 21st century:identifying risk in primary prevention, controlling risk in secondary prevention. Rev Esp Cardiol, 2012,65S2:3-9.
[45]WHO. The world health report 2002-reducing risks, promoting healthy life [M].Geneva:World Health Organization,2002.
[46]Shanthi Mendis.David Webber. Avoiding heart attacks and Strokes [M]. Geneva:World Health Organization,2005.
[47]尤莉莉,刘爱萍,钮文异等.心血管疾病的优先干预类型及综合危险因素控制策略[J].中国健康教育,2011,27(3)：214-217.
[48]Shah S, Singh K, Ali MK, et al. Improving diabetes care:Multi-component cardiovascular disease risk reduction strategies for people with diabetes in South Asia-The CARRS Multi-center Translation Trial [J]. Diabetes Res Clin Pract.2012 Oct 18.
[49]S.Sever Peter, Dahlof Bjorn, R.Poulter Neil. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):a multicentre randomised controlled trial [J]. The Lancet,2003,361(9364):1149.
[50]Peter G(?)de, Henrik Lund-Andersen, Hans-Henrik Parving, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes [J]. N Engl J Med 2008,358:580-591.
[51]徐晓峰,陈跃.肖文辉.心血管风险评估进展及面临的问题[J].心脑血管病防治,2009,9(6)：401-404.
[52]World Health Organization. Prevention of cardiovascular disease:Pocket Guidelines for Assessment and Management of Cardiovascular Risk [M]. WHO,2008.
[53]Lindstrom J, Peltonen M, Eriksson JG, et al. Improved lifestyle and decreased diabetes risk over 13 years:long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS) [J].Diabetologia,2012 Oct 24.
[54]John Danesh, Jeremy G. Wheeler, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease[J]. N Engl J Med,2004,50(14):1387-1397.
[55]Meguro S, Ishibashi M, Takei I. The significance of high sensitive C reactive protein as a risk factor for cardiovascular diseases[J]. Rinsho Byori,2012, 60(4):356-361.
[56]龚博君.内脂素与心血管病关系的研究进展.心血管病学进展,2011,32(6)：836-839.
[57]Filippatos TD, Randeva HS, Derdemezis CS, et al. Visfatin/PBEF and atherosclerosis-related diseases[J]. Curr Vasc Pharmacol,2010,8(1):12-28.
[58]Wang P, Vanhoutte PM, Miao CY. Visfatin and cardio-cerebro-vascular disease[J]. J Cardiovasc Pharmacol,2012,59(1):1-9.
[59]Peiro C, Romacho T, Carraro R, et al. Visfatin/PBEF/Nampt:A New Cardiovascular Target[J]? Front Pharmacol,2010,1:135.
[60]de Ruijter W, Westendorp RG, Assendelft WJ, et al. Use of Framingham Risk Score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study[J]. BMJ,2008,337:a3083.
[61]Kritchevsky SB, Cesari M, Pahor M. Inflammatory markers and cardiovascular health in older adults[J]. Cardiovasc Res,2005,66(2):265-75.
[62]Singh T, Newman AB. Inflammatory markers in population studies of aging[J]. Ageing Res Rev.2011,10(3):319-29.
[63]Bjorn Zethelius, Lars Berglund, et al. Use of Multiple Biomarkers to Improve the Prediction of Death from Cardiovascular Causes. The new england journal of medicine[J]. N Engl J Med,2008,358(20):2107-2116.
[64]Frazier L, Sparks E, Sanner JE, Henderson M. Biobanks and biomarker research in cardiovascular disease[J]. J Cardiovasc Nurs.2008,23(2): 153-158.
[65]Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes[J]. N Engl J Med 2008,358:2107-16.
[66]Gilstrap LG, Wang TJ. Biomarkers and cardiovascular risk assessment for primary prevention:an update[J]. Clin Chem.2012,58(1):72-82.
[67]Robinson JG, Rahilly-Tierney C, Lawler E, et al. Benefits associated with achieving optimal risk factor levels for the primary prevention of cardiovascular disease in older men[J]. J Clin Lipidol,2012,6(1):58-65.
[68]Rizkalla SW, Prifti E, Cotillard A, et al. Differential effects of macronutrient content in 2 energy-restricted diets on cardiovascular risk factors and adipose tissue cell size in moderately obese individuals:a randomized controlled trial[J]. Am J Clin Nutr.2012,95(1):49-63.
[69]Gogebakan O, Kohl A, Osterhoff MA, et al. Effects of weight loss and long-term weight maintenance with diets varying in protein and glycemic index on cardiovascular risk factors:the diet, obesity, and genes (DiOGenes) study:a randomized, controlled trial[J]. Circulation.2011,124(25):2829-38.
[70]Brett T, Arnold-Reed D, Phan C, et al. The Fremantle Primary Prevention Study:a multicentre randomised trial of absolute cardiovascular risk reduction[J]. Br J Gen Pract,2012,62(594):e22-8.
[71]Stacey L Sheridan, Lindy B Draeger, Michael P Pignonel, et al. A randomized trial of an intervention to improve use and adherence to effective coronary heart disease prevention strategies Sheridan et al[J]. BMC Health Services Research, 2011,11:331
[72]Jennifer G. Robinson, MD, MPH, et al. Benefits associated with achieving optimal risk factor levels for the primary prevention of cardiovascular disease in older men[J]. Journal of Clinical Lipidology,2012,6,58-65
[73]Ndumele CD, Baer HJ, Shaykevich S, et al. Cardiovascular disease and risk in primary care settings in the United States[J]. Am J Cardiol,2012, 109(4):521-526.
[74]Kirsten Bibbins-Domingo, Glenn M Chertow, Pamela G. et al. Projected effect of dietary salt reductions on future cardiovascular disease[J]. N Engl J Med,2010,362(7):590-599.
[75]Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER):a randomised controlled trial[J]. Lancet, 2002,360(9346):1623-1630.
[76]Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older[J]. N Engl J Med,2008,358(18):1887-1898.
[77]Peter Gaede, Henrik Lund-Andersen, Hans-Henrik Parving, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes[J]. N Engl J Med, 2008,358(6):580-591.
[78]Barbara J. Fletcher, Roberta Oka. Introduction:Successful lifestyle changes for cardiovascular risk reduction[J]. Journal of Cardiovascular Nursing,2010, 25(3):221-222.
[79]Wayne J Katon, Elizabeth HB. Lin, Michael Von Korff, et al. Trial of Lifestyle Modification and Pharmacotherapy for Obesity[J]. N Engl J Med, 2005,363(20):2111-2120.
[80]Do Peterson, Carolyn M Rutter, Mary McGregor, et al. Collaborative care for patients with depression and chronic illnesses[J]. N Engl J Med,2010,363(27): 2611-2620.
[81]Cao Y, Davidson PM, DiGiacomo M. Cardiovascular disease in China:an urgent need to enhance the nursing role to improve health outcomes[J]. J Clin Nurs,2009,18(5):687-93.
[82]Dorothy M Lanuza, Patricia M Davidson, Sandra B Dunbar, et al. Preparing nurses for leadership roles in cardiovascular disease prevention[J]. Journal of Cardiovascular Nursing,2011,26(4):856-863.
[83]Barbara J Fletcher, Cheryl Dennison Himmelfarb, Maria Teresa Lira, et al. Global cardiovascular disease prevention:a call to action for nursing community-based and public health prevention initiatives[J]. Journal of Cardiovascular Nursing,2011,26(4):535-545.
[84]郝元涛,方积乾.世界卫生组织生存质量测定量表中文版介绍及其使用说明[J].现代康复,2000,4(8)：1127-1129.
[85]杨晔,何疆春.心血管疾病多重危险因素的综合防治人民军医[J].2009,52(11)：707-708.
[86]Miller EL, Murray L, Richards L, et al. Comprehensive overview of nursing and interdisciplinary rehabilitation care of the stroke patient:a scientific statement from the American Heart Association[J]. Stroke,2010,41, 2402-2448.
[87]Tadros A, Crocco T, Davis SM, et al. Emergency medical services-based community stroke education:pilot results from a novel approach[J]. Stroke 2009,40,2134-2142.
[88]高美玲.综合性干预对代谢综合征患者多重危险因素及血浆脑钠肤水平的影响[D].硕士论文,内科学.青岛大学,2011.
[89]黄琼芳,韩全水,佘志红等.多重因素干预对代谢综合征患病率的影响[J].现代医药卫生,200723(4)：484-486.
[90]周祖勇,潘仰中,易旺东等.贵阳市社区人群代谢综合征多重危险因素干预前后的对比分析[J].中华高血压杂志,2008,16(10)：937-939.
[91]周祖勇,潘仰中,易旺东等.贵阳市社区人群代谢综合征多重危险因素干预前后的对比分析[J].中华高血压杂志,2008,16(10)：937-939.
[92]黄琼芳,韩全水,佘志红等.多重因素干预对代谢综合征患病率的影响[J].现代医药卫生,200723(4)：484-486.
[93]Chun-Ja Kim,Dae-Jung Kim,Hyung-Ran Park. Effects of a cardiovascular risk reduction intervention with psychobehavioral strategies for korean adults with type 2 diabetes and metabolic syndrome[J]. Journal of Cardiovascular Nursing, 2011,26(2):117-128.
[94]Defulio A, Silverman K. The use of incentives to reinforce medication adherence[J]. Prev Med,2012,55 Suppl:S86-94.
[95]Aikens JE, Piette JD.Longitudinal association between medication adherence and glycaemic control in Type 2 diabetes[J]. Diabet Med,2012 Oct 17. doi: 10.1111/dme.12046.
[96]Burda C, Haack M, Duarte AC, et al. Medication adherence among homeless patients:A pilot study of cell phone effectiveness[J]. J Am Acad Nurse Pract, 2012,24(11):675-81.
[97]陈卉.生活方式干预多重心血管病危险的研究进展[J].现代预防医学,2011,38(10)：1892-1894.
[98]杨瑞,龙靓,龚志成等.社区高血压患者血压控制影响因素及综合干预的调查分析[J].中国药房,2012,23(36)：3367-3370.
[99]刘莹原.发性高血压生活方式干预的疗效观察[J].实用心脑肺血管病杂志,2012,20(10)：1653-1654.
[100]楼君芳,宋平,潘建清等.慢病高危人群的健康生活方式干预效果评价[J].中国慢性病预防与控制,2012,20(3)：324-326.
[101]宋丽娟,王伟.生活方式干预对糖尿病前期患者的效果观察[J].中国临床医学.2012,19(4)：：422-423.
[102]王建骏,朱理敏,王丽芬.健康教育提高社区高血压患者服药依从性和高血压控制率[J].实用全科医学,2008,6(6)：607-608.
[103]傅东坡,傅华,Mc Gowan,等.上海慢性病自我管理项目实施效果的评价[J].中国公共卫生,2003,19(2)：223-2251.
[104]张丽丽,董建群.慢性病患者自我管理研究进展[J].中国慢性病预防与控制.2010,18(2)：207-210.
[105]张红叶,李申生,符英英,等.社区实施慢性病自我管理项目的研究[J].现代预防医学,2007,34(11)：2148-21492152.
[106]张桂娟,马民.护理干预对老年高血压患者血压水平和自我管理疾病能力的影响[J].中国老年学杂志,2010,30：34-36.
[107]张红叶,李申生,符英英,等.社区实施慢性病自我管理项目的研究[J].现代预防医学,2007,34(11)：2148-21492152.
[108]Henrike Elzen, Joris PJ Slaets, Tom AB, et al. Evaluation of the chronic disease self-management program (CDSMP) among chronically ill older people in the Netherlands[J].Soc Sci Med,2007:1832-1841.
[109]Henrike Elzen, Joris PJ Slaets, Tom AB, et al. Evaluation of the chronic disease self-management program (CDSMP) among chronically ill older people in the Netherlands[J]. Soc Sci Med,2007:1832-1841.
[110]Bentsen SB, Langeland E, Holm AL. Evaluation of self-management interventions for chronic obstructive pulmonary disease[J]. J Nurs Manag,2012, 20(6):802-13.
[111]李来有,李艳玲,康琳.慢性病自我管理方案在老年慢性病患者中的应用评价明.护士进修杂志,2012,27(11)：1055-1057.
[112]魏红丽.社区护理干预对老年慢性病患者生活质量的影响.中国实用医药,2011,6(33)：219-220.
[113]章旭玲,高玉霞,邢沈阳.长春市城市社区老年人生活质量调查研究[J].护理研究,2008,22,(10)：2558-2560.
[114]戴叶花,侯爱和,张平,等.慢性阻塞性肺疾病患者自我管理与生活质量相关性分析[J].齐鲁护理杂志,2012,18(3)：52-53.
[115]李新建,程旻娜,王玉恒,等.社区综合干预对高血压患者心血管风险的影响[J].中国慢性病预防与控制,2011,19(1)：87-90.
[116]屈雪莹.高密度脂蛋白在心血管代谢风险中的研究.国际心血管病杂志,2010,37(2)：81-84.
[117]Kathy Berra, Nancy Houston Miller, Catriona Jennings. Nurse-based models for cardiovascular disease prevention:from research to clinical practice[J]. Journal of Cardiovascular Nursing,2011,26(4):546-555.
[118]Taniguchi H, Momiyama Y, Ohmori R, et al. Associations of plasma C-reactive protein levels with the presence and extent of coronary stenosis in patients with stable coronary artery disease[J]. Atherosclerosis,2005,178(1):173-7.
[119]Burke AP, Rusell TP, Kolodgie F, et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death:association with different pathologies[J], Circulation,2002,105(17):2019-2023.
.[120] Kamioka M, Suzuki H, Yamada S.et al. High sensitivity c-reactive protein predicts nonresponders and cardiac deaths in severe heart failure patients after crt implantation[J]. Int Heart J,2012,53(5):306-12.
[121]Wu MH, Wang JH, Lai C, et al. Association of hs-CRP with the severity of coronary artery disease and myocardial infarction[J]. Int J Cardiol,2004, 97(suppl 2):S47-47.
[122]Mouridsen MR, Intzilakis T, Binici Z, et al. Prognostic value of high sensitive C-reactive protein in subjects with silent myocardial ischemia[J]. J Electrocardiol,2012 Jan 2
[123]Idemudia JO, Idogun ES. High sensitive C-reactive protein (HsCRP) as a cardiovascular risk factor in hypertensive Nigerians[J]. Niger Postgrad Med J, 2012,19(3):163-6.
[124]Hooten NN, Ejiogu N, Zonderman AB,et al. Association of oxidative DNA damage and C-reactive protein in women at risk for cardiovascular disease[J]. Arterioscler Thromb Vasc Biol,2012,32(11):2776-84.
[125]Poon PY, Szeto CC, Ching-Ha Kwan B, et al. Relationship between CRP polymorphism and cardiovascular events in Chinese peritoneal dialysis patients[J]. Clin J Am Soc Nephrol,2012 Jan 12.
[126]Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin:a protein secreted by visceral fat that mimics the effects of insulin [J]. Science,2005,307(5708): 426-430.
[127]Adya R, Tan BK, Chen J, et al. Visfatin and endothelial angiogenesis[J]. Cardiovasc Res,2012,96(2):223-6.
[128]Cirillo P, Di Palma V, Maresca F, et al. The adipokine visfatin induces tissue factor expression in human coronary artery endothelial cells:another piece in the adipokines puzzle[J]. Thromb Res,2012,130(3):403-8.
[129]Varma V, Yao-Borengasser A, Rasouli N, et al. Human visfatin expression: relationship to insulin sensitivity,intramyocellular lipids, and inflammation[J]. J Clin Endoerinal Metab,2007,92(12):666-672.
[130]Dahl TB, Holm S, Aukrust P, Halvorsen B. Visfatin/NAMPT:A multifaceted molecule with diverse roles in physiology and pathophysiology[J]. Annu Rev Nutr,2012,32:229-43.
[131]Filippatos TD, Tsimihodimos V, Derdemezis CS, Gazi IF, Saougos V, Mikhailidis DP, Tselepis AD, Elisaf MS. Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile[J]. Nutr Metab Cardiovasc Dis,2011 Oct 1.
[132]Liu SW, Qiao SB, Yuan JS, Liu DQ. Visfatin stimulates production of monocyte chemotactic protein-1 and interleukin-6 in human vein umbilical endothelial cells[J]. Horm Metab Res,2009,41(4):281-286.
[133]Lee WJ, Wu CS, Lin H, et al. Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway[J]. Int J Obes (Lond),2009,33(4):465-472.
[134]Gunes F, Akbal E, Cakir E, et al. Visfatin may be a novel marker for identifying stages of essential hypertension in advanced age patients[J]. Intern Med,2012, 51(6):553-7.
[135]Pervin V, Sevgin D, Neslihan YS, et al. Tumor necrosis factor α(-308), interleukin-6 (-174) and interleukin-10 (-1082) gene polymorphisms in polycystic ovary syndrome[J]. Euro J Obstet Gynecol Reprod Biol,2009, 150:61-65.
[136]李利辉,陈凯东,邹辉建.胰岛素抵抗、白细胞介素-6、肿瘤坏死因子-α与2型糖尿病合并冠心病相关性研究[J].中国临床保健杂志,2010,13(2)：171-172.
[137]黄炜,陈清枝,燕宪亮,等.C-反应蛋白白细胞介素-6和肿瘤坏死因子-α在冠心病中的变化[J].临床心血管病杂志,2004,20(7)：398-400.
[138]Voros K, Prohaszka Z, Kaszas E, et al. Serum Ghrelin Level and TNF-α/Ghrelin Ratio in Patients with Previous Myocardial Infarction. Arch Med Res.2012 Oct 15. Huang Y, Yan L, Rong S, et al. TNF-α induces endothelial dysfunction via PKC-ζ-dependent NADPH oxidase activation [J]. J Huazhong Univ Sci Technolog Med Sci,2012,32(5):642-7.
[139]Li L, Wu LL. Adiponectin and interleukin-6 in inflammation-associated disease[J]. Vitam Horm,2012,90:375-95.
[140]Febbraio M, Hajjar DP, Silverstein RL. CD36:a class B scavenger receptor involved in angioigenesis, atherosclerosis, inflammation, and lipid metabolism[J]. J Clin Invest,2001,108:785-791.
[141]Tangirala RK, Mol MJ, Steinberg D. Macrophage oxidative modification of low density lipoprotein occurs independently of its binding to the low density lipoprotein receptor[J]. J Lipid Res,1996,37:835-843.
[142]McLouphlin C. Statins[J]. Prof Nurse,2004,19(11):51-2.
[143]Raja SG, Dreyfus GD. Statins:much more than just a lipid-lowering therapy[J]. Indian Heart J,2004,56(3):204-9
[144]Liao JK. Statins:potent vascular anti-inflammatory agents. Int J Clin Pract Suppl.2004, (143):41-8.
[145]Haendeler J, Hoffmann J, Zeiher AM, et al. Antioxidant effects of statins via s-nitrosylation and activation of thioredoxin in endothelial cells [J]. Circulation, 2004,110(7):856-61.
[146]Shukla A, Sharma MK, Jain A, et al. Prevention of atherosclerosis progression using atorvastatin in normolipidemic coronary artery disease patients--a controlled randomized trial [J]. Indian Heart J,2005,57(6):675-80.
[147]Yamagishi S, Matsui T, Nakamura K. Atorvastatin and diabetic vascular complications [J]. Curr Pharm Des,2006,12(12):1549-54.
[148]Dahl TB, Yndestad A, Skjelland M, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis:possible role in inflammation and plaque destabilization [J]. Circulation,2007, 115:972-980
[1]Yu DS, Lee DT, Kwong AN, et al. Living with chronic heart failure:a review of qualitative studies of older people[J]. J Adv Nurs,2008,61(5):474-^83.
[2]Yang G, Kong L, Zhao W, et al. Emergence of chronic non-communicable diseases in China[J]. Lancet,2008,372(9650):1697-1705.
[3]World Health Organization. Global status report on non-communicable diseases 2010. Geneva, WHO,2010.
[4]Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation, 2004,109(9):1101-1107.
[5]Johnston SC, Mendis S, Mathers CD. Global variation in stroke burden and mortality:Estimates from monitoring, surveillance, and modeling. Lancet Neurology,2009,8(4):345-354.
[6]Brindle P, Beswick A, Fahey T, et al. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease:a systematic review[J]. Heart, 2006,92(12):1752-1759.
[7]Wister A, Loewen N, Kennedy-Symonds H, et al. One-year follow-up of a therapeutic lifestyle intervention targeting cardiovascular disease risk[J]. CMAJ, 2007,177(8):859-865.
[8]Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases Part I:general considerations, the epidemiologic transition, risk factors, and impact of urbanization[J]. Circulation,2001,104(22):2746-2753.
[9]World Health Organization. The atlas of heart disease and stroke 2004. Geneva: WHO,2004.
[10]World Health Organization. Global atlas on cardiovascular disease prevention and control 2011, Geneva:WHO,2011.
[11]Brindle P, Beswick A, Fahey T, et al. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease:a systematic review. Heart, 2006,92(12):1752-1759.
[12]Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases Part Ⅱ:Global burden of cardiovascular diseases:Part Ⅱ:variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies[J]. Circulation,2001,104(23):2855-2864.
[13]Sen K, Bonita R. Global health status:two steps forward, one step back[J]. Lancet,2000,356(9229):577-582.
[14]Sasayama S. Heart disease in Asia[J]. Circulation,2008,118(25):2669-2671.
[15]Mozaffarian D, Kamineni A, Prineas RJ, et al. Metabolic syndrome and mortality in older adults:the Cardiovascular Health Study[J]. Arch Intern Med, 2008,168 (9):969-978.
[16]Shahwan-Akl L. Cardiovascular disease risk factors among adult Australian-Lebanese in Melbourne[J]. Int J Res Nursing,2010,6(1):1-7.
[17]Hong Y. Burden of Cardiovascular Disease in Asia:Big Challenges and Ample Opportunities for Action and Making a Difference [J]. Clin Chem,2009,55(8): 1450-1452.
[18]Patel K, Minhas R, Gill P, et al. Vascular risk checks in the UK:strategic challenge s for implementation[J]. Heart,2009,95(11):866-867.
[19]UK Department of Health. Putting prevention first -vascular checks:risk assessment and management. Annex 1:options stage impact assessment for vascular risk assessments, LONDON,2008.
[20]Puska P. From Framingham to North Karelia:From descriptive epidemiology to public health action[J]. Progress in Cardiovascular Diseases,2010,53(1): 15-20.
[21]Kita Y, Turin TC, Ichikawa M, et al. Trend of stroke incidence in a Japanese population:Takashima stroke registry,1990-2001 [J]. International Journal of Stroke,2009,4(4):241-249.
[22]Galus DF, Zejda JE. Decreasing trend of cardiovascular mortality in Poland in the years 1980-2001 [J]. Wiad Lek,2004,57(Suppl.1):85-86.
[23]Leeder S et al. A race against time:the challenge of cardiovascular disease in developing economies. New York, The Center for Global Health and Economic Development,2004.
[24]He J, Gu D, Wu X, et al. Major causes of death among men and women in China[J]. N Engl J Med,2005,353(11):1124-1134.
[25]Zhang L, Qin LQ, Cui HY, et al. Prevalence of cardiovascular risk factors clustering among suburban residents in Beijing, China[J]. Int J Cardiol,2011, 151(1):46-49.
[26]中华人民共和国卫生部.中国心血管病报告2011[R].北京：中国大百科全书出版社,2012：1-2.
[27]Lao XQ, Zhang YH, Wong MC, et al. The prevalence of metabolic syndrome and cardiovascular risk factors in adults in southern China[DB/OL] [J]. BMC Public Health,2012,21(12):64,
[28]Gu D, Reynolds K, Wu X, et al. Prevalence of the metabolic syndrome and overweight among adults in China[J]. Lancet,2005,365(9468):1398-1405.
[29]Wang SX, Xue H, Zou YB, et al. Prevalence and risk factors for left ventricular hypertrophy and left ventricular geometric abnormality in the patients with hypertension among Han Chinese[J]. Chin Med J (Engl),2012,125(1):21-26.
[30]Wu Z, Yao C, Zhao D, et al. Sino-MONICA project:a collaborative study on trends and determinants in cardiovascular diseases in China, Part i:morbidity and mortality monitoring[J]. Circulation,2001,103(3):462-468.
[31]Li XJ, Cheng MN, Wang YH, et al. Effectiveness of lifestyle intervention for hypertension in Shanghai communities:Results from the Shanghai[J]. Front Med China,2010,4(1):67-70.
[32]贾杰,周瑛.社区医疗卫生服务中存在的问题及建议[J].中国医药指南,2012,10(18)：678-679.
[33]Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients-the treatment-risk paradox[J]. JAMA,2004,291(15): 1864-1870.
[34]GU D, Wildman RP, Wu X, et al. Incidence and predictors of hypertension over 8 years among Chinese men and women[J]. J Hypertens,2007,25(3):517-523.
[35]Driscoll A, Beauchamp A, Lyubomirsky G,et al. Suboptimal management of cardiovascular risk factors in coronary heart disease patients in primary care occurs particularly in women[J]. Intern Med J,2011,41(10):730-736.
[36]王薇,赵冬,孙佳艺,等.中国正常高值血压人群的心血管病发病风险[J].中华心血管病杂志,2007,15(12)：984-987.
[37]Yang JM, Lu FH, Zhang C, et al. Prevalence of prehypertension and hypertension in a Chinese rural area from 1991 to 2007[J]. Hypertension Research,2010,33(4):331-337.
[38]Godley P, Pham H, Rohack J,_et al. Opportunities for improving the quality of hypertension care in a managed care setting[J]. Am J Health Syst Pharm,2001, 58 (18):1728-1733.
[39]Hu DY, Li J, Li XK, et al. Investigation of blood lipid levels and stain interventions in outpatients with coronary heart disease in China[J]. Circ J, 2008,72(12):2040-2045.
[40]Karalis DG. Intensive lowering of low-density lipoprotein cholesterol levels for primary prevention of coronary artery disease[J]. Mayo Clin Proc,2009,84(4): 345-352.
[41]Farzadfar F, Finucane MM, Danaei G, National, regional, and global trends in serum total cholesterol since 1980:systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants[J]. Lancet,2011,377(9765):578-586.
[42]Wang S, Xu L, Jonas JB, et al. Prevalence and associated factors of dyslipidemia in the adult Chinese population[J]. PLoS One,2011,6(3):e17326.
[43]Boden-Albala B, Cammack S, Chong J, et al. Diabetes, fasting glucose levels, and risk of ischemic stroke and vascular events:Findings from the Northern Manhattan Study (NOMAS)[J]. Diabetes Care,2008,31(6):1132-1137.
[44]Eberly LE, Cohen JD, Prineas R, et al. Intervention Trial Research Group. Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality:The multiple risk factor intervention trial experience [J]. Diabetes Care,2003,26(3):848-854.
[45]Yang WY, Lu JM, Weng JP, et al. Prevalence of diabetes among men and women in China[J]. N Eng J Med,2010,362(12):1090-1101.
[46]Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study:a 20-year follow-up study[J]. Lancet,2008,371(9626):1783-1789.
[47]World Health Organization. The global burden of disease:2004 update. Geneva, WHO,2008.
[48]World Health Organization. Global health risks:Mortality and burden of disease attributable to selected major risks. Geneva, WHO,2009.
[49]He J, Gu D, Wu X, et al. Major cause of death among men and women in China[J]. N Eng J Med,2005,353(11):1124-1134.
[50]Gu D, Kelly TN, Wu X, et al. Mortality attributable to smoking in China[J]. N Eng J Med,2009,360(2):150-159.
[51]Doll R, Peto R, Boreham J et al. Mortality in relation to smoking:50 years' observations on male British doctors[J]. BMJ,2004,328(7455):1519.
[52]Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980:Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants[J]. Lancet,2011,337(9765):557-567.
[53]WHO. Obesity:Preventing and managing the global epidemic. Report of a WHO Consultation. Geneva, World Health Organization,2000.
[54]孙佳艺,赵冬,王微,等.体重指数对10年累计高血压发病危险的预测作用 [J].中华流行病学杂志,2009,30(5)：435-438.
[55]World Health Organization. Global status report on non-communicable diseases 2010:Geneva, WHO,2010.
[56]Ng S, Norton E, Popkin B. Why have physical activity levels declined among Chinese adults? Findings from the 1991-2006 China health and nutrition surveys[J]. Social Science & Medicine,2009,68(7):1305-1314.
[57]Kotseva K, Wood D, De Backer G, et al. EUROASPIRE Ⅲ. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice:Cross-sectional survey in 12 European countries[J]. European Journal of Cardiovascular Prevention and Rehabilitation,2010,17(5):530-540.
[58]翟凤英杨晓光.2002年中国居民营养与健康状况调查报告之二：膳食与营养素摄入情况[R].北京：人民卫生出版社,2006.7.
[59]Rehm J, Baliunas D, Borges GL, The relation between different dimensions of alcohol consumption and burden of disease:An overview[J]. Addiction,2010, 105(5):817-843.
[60]O'Keefe JH, Bybee KA, Lavie CJ. Alcohol and cardiovascular health:The razor-sharp double-edged sword[J]. J Am Coll Cardiol,2007,50(11): 1009-1014.
[61]Rozanski A, Blumenthal JA, Davidson KW, et al. The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice:the emerging field of behavioral cardiology [J]. J Am Coll Cardiol, 2005,45(5):637-651.
[62]Steinberg JS, Arshad A, Kowalski M, et al. Increased incidence of life threatening ventricular arrhythmias in implantable defibrillator patients after the World Trade Center attack[J]. J Am Coll Cardiol,2004,44(6):1261-1264.
[63]Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030[J]. PLoS Med,2006,3(11):e442.
[64]Jackson R, Lynch J, Harper S. Preventing coronary heart disease[J]. BMJ, 2006,332 (7542):617-618.
[65]D'Agostino RB Sr, Grundy S, Sullivan LM, et al. CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores:results of a multiple ethnic groups investigation[J]. JAMA,2001,286(2):180-187.
[66]Marrugat J, D'Agostino R, Sullivan L, et al. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas[J]. J Epidemiol Community Health,2003,57(8):634-638.
[67]Conroy RM, Pyorala K, Fitzgerald AP, et al. SCORE Project Group. Estimation of ten-year risk of fatal cardiovascular disease in Europe:the SCORE project[J]. Eur Heart J,2003,24(11):987-1003.
[68]Ridker PM, Paynter NP, Rifai N, et al. C-reactive Protein and parental history improve global cardiovascular risk prediction:the Reynolds Risk Score for men[J]. Circulation,2008,118(22):2243-2251.
[69]World Health Organization. WHO/ISH cardiovascular risk prediction charts. Geneva:WHO,2008.
[70]刘静,赵冬,王薇,等.中国多省市心血管病危险因素队列研究与美国弗莱明翰心脏研究结果的比较[J].中华心血管病杂志,2004,32(2)：167-172.
[71]Wu Y, Liu X, Li X, et al. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults[J]. Circulation,2006, 114(21):2217-2225.
[72]Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study):case-control study[J]. Lancet,2004,364(9438): 937-952.
[73]Tonkin AM, Lim SS, Schirmer H:Cardiovascular risk factors:when should we treat? [J]. MJA,2003,178(3):101-102.
[74]World Health Organization. Prevention of cardiovascular disease:guidelines for assessment and management of total cardiovascular risk. Geneva:WHO,2007.
[75]Webster RJ, Heeley EL, Peiris DP, et al. Gaps in cardiovascular disease risk management in Australian general practice[J]. MJA,2009,191(6):324-329.
[76]UK Department of Health. Preventing CHD in high-risk patients. In:Coronary heart disease:National Service Framework for Coronary Heart Disease Modern standards and service models. Chapter 2, London 2000.
[77]徐晓峰,陈跃,肖文辉.心血管风险评估进展及面临的问题[J].心脑血管病防治.2009,12(9)：401-404.
[78]Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations,in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):a multicentre randomised controlled trial[J]. Lancet,2003,361 (9364):1149-1158.
[79]尤莉莉,刘爱萍,钮文异,等.心血管疾病的优先干预类型及综合危险因素控制策略[J].中国健康教育,2011,27(3)：214-217.
[80]World Health Organization. Prevention of cardiovascular disease:Pocket Guidelines for Assessment and Management of Cardiovascular Risk. WHO, 2008.
[81]Erhardt L, Moller R, Puig JG Comprehensive cardiovascular risk management-what does it mean in practice?[J]. Vasc Health Risk Manag,2007,3(5): 587-603.
[82]Juonala M, Viikari JS, Kahonen M,et al. Life-time risk factors and progression of carotid atherosclerosis in young adults:the cardiovascular risk in young Finns study[J]. Eur Heart J,2010,31(14):1745-1751.
[83]Ludt S, Wensing M, Szecsenyi J,et al. Predictors of health-related quality of life in patients at risk for cardiovascular disease in European primary care[J]. PLoS One,2011,6(12):e29334.
[84]Ansell BJ. Evidence for a combined approach to the management of hypertension and dyslipidemia[J]. Am J Hypertens,2005,18(9 Pt 1): 1249-1257.
[85]Bhatt DL, Steg PQ Ohman EM,et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis[J]. JAMA,2006,295(2):180-189.
[86]Gaede P, Lund-Andersen H, Parving HH,et al. Effect of a multifactorial intervention on mortality in type 2 diabetes[J]. N Engl J Med,2008,358(6):580-591.
[87]Mancia G Total cardiovascular risk:a new treatment concept[J]. J Hypertens Suppl,2006,24(2):S17-24.
[88]British Cardiac Society, British Hypertension Society, Diabetes UK, et al. JBS 2:Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice[Z]. Heart,2005,91 (Suppl 5):v1-52.
[89]Mazon-Ramos P. Cardiovascular Risk in the 21st Century:Identifying Risk in Primary Prevention. Controlling Risk in Secondary Prevention[J]. Rev Esp Cardiol,2012,65(S2):3-9.
[90]Willis A, Davies M, Yates T, et al. Primary prevention of cardiovascular disease using validated risk scores:A systematic review[J]. J R Soc Med,2012,105(8): 348-356.
[91]Cobiac LJ, Magnus A, Lim S, et al. Which interventions offer best value for money in primary prevention of cardiovascular disease?[J]. PLoS One,2012, 7(7):e41842.
[92]Neuner-Jehle S, Senn O, Wegwarth O, et al. How do family physicians communicate about cardiovascular risk? Frequencies and determinants of different communication formats[J]. BMC Fam Pract,2011,12:15.
[93]Chiuve SE, McCullough ML, Sacks FM, et al. Healthy lifestyle factors in the primary prevention of coronary heart disease among men:benefits among users and nonusers of lipid-lowering and antihypertensive medications[J]. Circulation, 2006,114(2):160-167.
[94]Clark RA, Inglis SC, McAlister FA, et al. Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis[J]. BMJ,2007,334(7600):942.
[95]Ward AM, Heneghan C, Perera R, et al. What are the basic self-monitoring componentsfor cardiovascular risk management?[J]. BMC Med Res Methodol, 2010,10:105.
[96]Katon WJ, Lin EH, Von Korff M, et al. Collaborative Care for Patients with Depression and Chronic Illesses[J]. N Engl J Med,2010,363(27):2611-2620.
[97]Voogdt-Pruis HR, Beusmans GH, Gorgels AP, Kester AD,et al. Effectiveness of nurse-delivered cardiovascular risk management in primary care:a randomised trial[J]. Br J Gen Pract,2010,60(570):40-46.